Products for Research Use Only

(R) -AR-13503

CAT: 0804-HY-12798E-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12798E-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(R) -AR-13503 ((R) -AR-13324 M1 metabolite) is the the (R) -enantiomer of AR-13503. AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research[1][2][3].
CAS Number
2377238-62-3
Product Name Alternative
(R) -AR-13324 M1 metabolite
UNSPSC
12352005
Target
Drug Metabolite; PKC; ROCK
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Purity
98.20
Smiles
OCC1=CC=C([C@H](CN)C(NC2=CC(C=CN=C3)=C3C=C2)=O)C=C1
Molecular Formula
C19H19N3O2
Molecular Weight
321.37
References & Citations
[1]Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 205-205.|[2]Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 200-200.|[3]Halasz E, et al. AR-13503, a ROCK inhibitor, reduces rod axon retraction during retinal detachment[J]. Investigative Ophthalmology & Visual Science, 2018, 59 (9) : 4221-4221.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported